This is the first in vivo demonstration of combinatorial activity of an mTOR inhibitor with a BRAF inhibitor in gliomas, and will inform future clinical trials in pediatric brain tumor patients (Dasgupta et al., 2013). The gene discussed is BRAF; the disease is central nervous system cancer.